PCSK9 Inhibition in Transition: From Established Treatments to Emerging Therapeutic Approaches

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted proprotein convertase that promotes lysosomal degradation of the hepatic low-density lipoprotein receptor (LDLR), thereby reducing the clearance of circulating low-density lipoprotein cholesterol (LDL-C). Its validation as a therapeutic target is supported by human genetic evidence demonstrating that loss-of-function variants are associated with lifelong reductions in LDL-C and protection against cardiovascular disease. This review examines the biology of PCSK9 and the expanding range of strategies for its pharmacological inhibition, integrating evidence from human genetic studies, clinical trials, and preclinical models, with particular emphasis on translational relevance. The monoclonal antibodies evolocumab and alirocumab substantially reduce LDL-C levels and cardiovascular risk, whereas inclisiran, a small interfering RNA (siRNA), achieves sustained suppression of hepatic PCSK9 synthesis with infrequent dosing. Recent therapeutic advances include the FDA approvals of lerodalcibep, a third-generation injectable PCSK9 inhibitor, and enlicitide decanoate, an orally administered macrocyclic peptide inhibitor. In parallel, nanoparticle-based delivery systems, active PCSK9 vaccination, and CRISPR-based genome editing represent emerging therapeutic strategies that remain largely in preclinical development. Beyond cardiovascular disease, PCSK9 has been implicated in sepsis, cancer, and neurodegenerative, pulmonary, and autoimmune disorders, although the supporting evidence remains heterogeneous and predominantly preclinical. In oncology, experimental findings implicating PCSK9 in tumor immune evasion and modulation of responses to immune checkpoint blockade have prompted its clinical evaluation as a potential adjunct to anticancer therapy. Further prospective clinical studies are required to establish the efficacy and long-term safety of novel PCSK9-targeted approaches and determine whether their therapeutic potential translates into meaningful clinical benefits.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-18
DOI
https://doi.org/10.3390/ijms272210372
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PCSK9 Inhibition in Transition: From Established Treatments to Emerging Therapeutic Approaches

Iordanis S. Mourouzis, Dimitris C. Kounatidis, Constantinos I. Pantos, Anastasia Papagiannidou
1 links
International Journal of Molecular Sciences
Lipoproteins and Cardiovascular Health
article

PCSK9 Inhibition in Transition: From Established Treatments to Emerging Therapeutic Approaches

Iordanis S. Mourouzis, Dimitris C. Kounatidis, Constantinos I. Pantos, Anastasia Papagiannidou
article en

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secreted proprotein convertase that promotes lysosomal degradation of the hepatic low-density lipoprotein receptor (LDLR), thereby reducing the clearance of circulating low-density lipoprotein cholesterol (LDL-C). Its validation as a therapeutic target is supported by human genetic evidence demonstrating that loss-of-function variants are associated with lifelong reductions in LDL-C and protection against cardiovascular disease. This review examines the biology of PCSK9 and the expanding range of strategies for its pharmacological inhibition, integrating evidence from human genetic studies, clinical trials, and preclinical models, with particular emphasis on translational relevance. The monoclonal antibodies evolocumab and alirocumab substantially reduce LDL-C levels and cardiovascular risk, whereas inclisiran, a small interfering RNA (siRNA), achieves sustained suppression of hepatic PCSK9 synthesis with infrequent dosing. Recent therapeutic advances include the FDA approvals of lerodalcibep, a third-generation injectable PCSK9 inhibitor, and enlicitide decanoate, an orally administered macrocyclic peptide inhibitor. In parallel, nanoparticle-based delivery systems, active PCSK9 vaccination, and CRISPR-based genome editing represent emerging therapeutic strategies that remain largely in preclinical development. Beyond cardiovascular disease, PCSK9 has been implicated in sepsis, cancer, and neurodegenerative, pulmonary, and autoimmune disorders, although the supporting evidence remains heterogeneous and predominantly preclinical. In oncology, experimental findings implicating PCSK9 in tumor immune evasion and modulation of responses to immune checkpoint blockade have prompted its clinical evaluation as a potential adjunct to anticancer therapy. Further prospective clinical studies are required to establish the efficacy and long-term safety of novel PCSK9-targeted approaches and determine whether their therapeutic potential translates into meaningful clinical benefits.

International Journal of Molecular SciencesVol. 27(22)
National and Kapodistrian University of Athens (GR)
Good health and well-being
Lipoproteins and Cardiovascular Health
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon